Valeant Pharmaceuticals, Inc.

Company Summary

A multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics..

Transaction Overview

On 18 February 2011, Valeant acquired NeutraSal by way of its purchase of Invado Pharmaceuticals for ~ $20 million cash
In addition to cash consideration paid at close, an escrow was established to underlie the representations and warrantees of the transaction
Following the acquisition, Invado suffered operational disruptions in the supply for NeutraSal which resulted in the removal of NeutraSal from the market for a period of 12 months.

‍

Significance of the Transaction

Given disruption associated with the recall of NeutraSal, Valeant negotiated a resolution to the escrow associated with its acquisition of Invado, thereby permitting the normalization of business operations.

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Strategic Advisory

Valeant Pharmaceuticals, Inc.

Has provided fairness opinion relating to its acquisition of

The undersigned acted as financial advisor to Valeant Pharmaceuticals